These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16439881)

  • 21. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
    Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
    J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
    Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
    HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
    Akerele T; Galatowicz G; Bunce C; Calder V; Lynn WA; Lightman S
    Clin Immunol; 2006 Nov; 121(2):191-7. PubMed ID: 16987710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy.
    Benito JM; López M; Lozano S; González-Lahoz J; Soriano V
    J Infect Dis; 2008 Nov; 198(10):1466-73. PubMed ID: 18847371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment.
    Sarmati L; Andreoni C; Nicastri E; Tommasi C; Buonomini A; D'Ettorre G; Corpolongo A; Dori L; Montano M; Volpi A; Narciso P; Vullo V; Andreoni M
    J Med Virol; 2009 Mar; 81(3):481-7. PubMed ID: 19152399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Untangling the immunological implications of nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy.
    Ferraris L; Bellistri GM; Pegorer V; Tincati C; Meroni L; Galli M; Monforte Ad; Gori A; Marchetti G
    Clin Infect Dis; 2008 Jan; 46(1):149-50. PubMed ID: 18171234
    [No Abstract]   [Full Text] [Related]  

  • 29. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort.
    Matheron S; Damond F; Benard A; Taieb A; Campa P; Peytavin G; Pueyo S; Brun-Vezinet F; Chene G;
    AIDS; 2006 Feb; 20(3):459-62. PubMed ID: 16439883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy.
    Marchetti G; Bellistrì GM; Borghi E; Tincati C; Ferramosca S; La Francesca M; Morace G; Gori A; Monforte AD
    AIDS; 2008 Oct; 22(15):2035-8. PubMed ID: 18784466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
    Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
    Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.
    Madec Y; Laureillard D; Pinoges L; Fernandez M; Prak N; Ngeth C; Moeung S; Song S; Balkan S; Ferradini L; Quillet C; Fontanet A
    AIDS; 2007 Jan; 21(3):351-9. PubMed ID: 17255742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART.
    Maggiolo F; Airoldi M; Callegaro A; Martinelli C; Dolara A; Bini T; Gregis G; Quinzan G; Ripamonti D; Ravasio V; Suter F
    AIDS; 2009 Apr; 23(7):799-807. PubMed ID: 19114869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome.
    Voirin N; Routy JP; Smith D; Baratin D; Trépo C; Cotte L; Touraine JL; Livrozet JM; Cooper DA; Ritter J; André P; Vanhems P
    HIV Med; 2008 Jul; 9(6):440-4. PubMed ID: 18705761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
    J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensification of a suppressive HAART regimen increases CD4 counts and decreases CD8+ T-cell activation.
    Kolber MA; Saenz MO; Tanner TJ; Arheart KL; Pahwa S; Liu H
    Clin Immunol; 2008 Mar; 126(3):315-21. PubMed ID: 17997138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency.
    Micheloud D; Berenguer J; Bellón JM; Miralles P; Cosin J; de Quiros JC; Conde MS; Muñoz-Fernández MA; Resino S
    J Infect; 2008 Feb; 56(2):130-6. PubMed ID: 18192020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.